This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Angiotech Buys Private Firm

Shares of Angiotech Pharmaceuticals (ANPI) were getting a lift Wednesday after the drug and device maker said it agreed to acquire privately held American Medical Instruments.

The $785 million acquisition will be funded by a $600 million loan and about $200 million in cash, according to the company. The transaction is expected to close in the second quarter and should immediately add to earnings.

Angiotech's stock was up $1.44, or 11.5%, to $14.02 on heavy volume. Angiotech says the acquisition will provide it with several new product opportunities and drive long-term growth. The combined company will focus on general, plastic and ophthalmic surgery, as well as performing vascular surgery, interventional radiology and tumor biopsies.

"The acquisition of AMI significantly diversifies Angiotech's revenue base and gives the company global manufacturing, marketing and sales capabilities," the company said in a press release Wednesday.

American Medical's revenue last year is estimated at $174 million, Angiotech said, representing around 46% of the combined revenue the two companies would have had in 2005 if they were already merged. For the nine-month period ended Sept. 30, Angiotech had revenue of $159.8 million.

Currently, Angiotech is probably best known for providing a drug called paclitaxel that's used on Boston Scientific's (BSX - Get Report) drug-coated Taxus stent.

The company recently acquired drug-delivery assets from Edwards Lifesciences (EW - Get Report), including a type of surgical sealant and experimental drug-eluting catheter technologies.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BSX $18.27 0.00%
EW $130.72 0.00%
AAPL $130.28 0.00%
FB $79.19 0.00%
GOOG $532.11 0.00%

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs